GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Cash Payments

Cantargia AB (FRA:7V3) Cash Payments


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


Cantargia AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.